Replies to post #79946 on DNAprint Genomics (DNAG)

[sam1933]

The postgenome era promises more efficient drug-development cycles and medications targeted to compatible populations, resulting in improved outcomes, fewer drug-company failures, less litigation, fewer recalls and a refurbished image of 'pharma' in the mind of the customer. DNAPrint was founded to help precipitate these changes. Since 1999, we have developed and optimized novel methods for assessing patient response proclivities as individuals but also as constituents of populations, and we have introduced a computational platform for modeling drug biology. We expect these tools will allow us to maximize the efficiency of our clinical trials and, more importantly, ensure better postmarket performance parameters. With these tools, we are now carefully engineering select drug-development projects in an attempt to illustrate the viability of a novel drug-development model - one based on the application of intelligence and new technologies for superior drug performance in segmented markets.
http://www.futuremedicine.com/doi/abs/10.2217/14622416.9.2.247?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov